Literature DB >> 2789507

Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.

G L Cushing1, J W Gaubatz, M L Nava, B J Burdick, T M Bocan, J R Guyton, D Weilbaecher, M E DeBakey, G M Lawrie, J D Morrisett.   

Abstract

Lp[a] is a lipoprotein whose plasma concentration is highly correlated with cardiovascular disease. Its protein moiety, apoLp[a], consists of two large polypeptides, apo[a] and apo B. The possible contribution of Lp[a] to atherosclerosis in saphenous vein aortocoronary bypass grafts was studied in a population of patients undergoing coronary re-bypass surgery. The vein graft tissue levels of apoLp[a] were compared with graft duration, gross and light microscopic pathology, as well as plasma levels of apoLp[a]. The localization pattern of apo[a] and apo B in vein graft tissue was determined. In addition, the plasma levels of cholesterol, triglycerides, apoproteins (apo) A-I, A-II, and E were measured. In a representative subpopulation of 17 patients with a mean age of 63 years from whom grafts with a mean duration of 112 months were resected, the mean total plasma cholesterol level was 221 mg/dl, the mean high density lipoprotein cholesterol level was 31 mg/dl, and the mean plasma triglyceride level was 228 mg/dl. In normal saphenous veins, the level of apoLp[a] was below measurable limits (less than 2 ng/mg), and the level of apo B was very low (3.3 ng/mg). In resected grafts, the mean tissue level of apoLp[a] was 32 ng/mg, and that of apo B was 70 ng/mg, demonstrating the net accumulation of these apoproteins in veins from the time of their grafting into the arterial bed. The apoLp[a]/apo B ratio was determined in 77 tissue segments from 59 grafts (28 patients) and was found to be 0.313. This tissue ratio was significantly higher (p = 0.02) than the plasma apoLp[a]/apo B ratio from these patients, which was 0.132. Immunostaining showed co-localization of apo[a] and apo B in the neointima of grafts. The most abundant pathologic features observed in resected grafts were proliferated intima (43/52), thrombus (28/52), and atherosclerotic core regions (21/52). The level of tissue apo B correlated well with the abundance of core regions (r = 0.501), whereas the level of tissue apoLp[a] did not correlate as well with this feature (r = 0.233). Although apo[a] and apo B are almost absent from normal saphenous vein, these apoproteins (and presumably the lipoproteins Lp[a] and low density lipoprotein) accumulate in bypass vein grafts. The data support the view that these lipoproteins play a significant role in vein graft atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789507     DOI: 10.1161/01.atv.9.5.593

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  33 in total

Review 1.  Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role.

Authors:  A M Scanu
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

2.  Lp(a): a link between thrombosis and atherosclerosis.

Authors:  A M Scanu
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

3.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.

Authors:  O Klezovitch; C Edelstein; A M Scanu
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

5.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; K Piper; H A Neil; P C Adams
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 6.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

8.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

9.  Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

Authors:  Menggui Huang; Yanqing Gong; Jessica Grondolsky; Jane Hoover-Plow
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

10.  Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.

Authors:  Kasey C Vickers; Colin T Maguire; Robert Wolfert; Alan R Burns; Michael Reardon; Richard Geis; Paul Holvoet; Joel D Morrisett
Journal:  J Lipid Res       Date:  2009-04-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.